(Press-News.org) Berlin, Germany: While influenza infection is a significant public health threat, causing serious illness in between three and five million people worldwide per year and leading to about up to 650,000 deaths, the effectiveness of influenza vaccines varies considerably between individuals depending on vaccine types and individual circumstances. A person’s ability to resist infection (host immunity) plays an important role in this. Now, researchers have developed a way of classifying host immunity in individuals, which may lead to the early identification of those who will not respond well to a regular vaccine schedule and therefore allow them to receive different vaccine regimes to provide them with long-lasting immunity. This will not only reduce influenza-related illness but also reduce the logistical and financial burden it causes to healthcare systems, they say.
Presenting the results of their study to the annual conference of the European Society of Human Genetics today (Monday), Dr Nhan Nguyen, a postdoctoral researcher at Professor Yang Li’s group, from the Centre for Individualised Infection Medicine, a joint venture of the Helmholtz Centre for Infection Research and Hannover Medical School, Hannover, Germany, and colleagues will describe how they took blood samples from 286 healthy donors aged 18-81, 45% of whom were women, during four influenza seasons in order to try to identify those who would be unprotected against influenza after vaccination.
“After examining their pre- and post-vaccination antibody status, we used multiomics1 technology to identify proteins and metabolites that could serve as predictive markers for the identification of individuals who have low levels of protection even after vaccination’”, says Dr Nguyen. “This is a more sophisticated way of identifying such people than that which is used at present, where protection is assessed solely by changes in the number of antibodies in the blood pre- and post-vaccination.”
The influenza vaccine is updated every year in response to variations in the virus, and this means that the pre-vaccination antibody level can differ in individuals due to previous infection or their vaccination history. The current vaccine response calculation may therefore not provide host-specific information that is sufficiently accurate to estimate a person’s immune response and/or vulnerability to future infections, since some people already have high antibody levels at pre-vaccination that do not change significantly after they have received a vaccine.
The results were consistent over the four flu seasons and the four different updates of the flu vaccines. “Each seasonal influenza vaccine is designed to protect against three or four different flu viruses, so a lot of factors are involved in an individual’s vaccine response. We aimed to identify the robust signals of response that spanned across different influenza seasons and were consistent despite the variations in the response of the same individual to different flu viruses,” says Dr Nguyen.
The researchers hope that the biomarkers they have identified as being related to an individual’s vaccine response will enable the development of personalised influenza vaccine administration, for example, higher dose vaccines, repeated vaccinations, or vaccines including an adjuvant to boost response. These biomarkers in turn will reduce the cost of vaccine response screening, as well as increasing protection against infection. They believe that their research could lead to the development of individualised adapted strategies for the administration of influenza vaccines.
“We are now testing a molecule that could act potentially as a predictive biomarker as well as a modulator of influenza vaccine response. We are also exploring the possibility of developing a market product such as a diagnostic test based on our results. And we hope to further explore the idea of personalised influenza vaccination based on the biomarkers we have identified in this study,” Dr Nguyen concludes.
Professor Alexandre Reymond, from the Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland, and chair of the conference, said: “Personalised health is all about identifying the fraction of individuals of the population who are at risk in order to be able to treat them specifically. Importantly, this will benefit these individuals and decrease the burden on the health system, which in turn will benefit everybody.”
(ends)
1.Multiomics is an approach to biological analysis that combines various ‘ome’ datasets, which are high-throughput measurements from genome, proteome, transcriptome, epigenome, and metabolome.
Abstract no. C24.4 A collective influence of genetic background on influenza vaccinees responses
END
New biomarkers will enable personalised influenza vaccination schedule
2024-06-03
ELSE PRESS RELEASES FROM THIS DATE:
Understanding how abnormal embryos self-correct may provide women with a better chance of IVF pregnancy
2024-06-03
Berlin, Germany: Aneuploidy (the presence of an abnormal number of chromosomes) in embryos is a major cause of impaired embryo development, leading to conditions such as Down syndrome, as well as to pregnancy loss. The transfer of such embryos in women undergoing IVF is therefore usually avoided because of unfavourable pregnancy outcomes. But mosaic embryos, comprising both genetically normal and abnormal cells, can result in perfectly normal babies. Now, researchers have been able to understand how these mosaic ...
Metformin may be as safe as insulin during pregnancy, 11-year data shows
2024-06-02
BOSTON—Metformin is safe to use during pregnancy to manage diabetes, with no long-term adverse effects on the children born and their mothers for at least 11 years after childbirth, according to research presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. This is the first study to look at longer term effects of metformin use during pregnancy.
“Metformin has been extensively used for managing raised blood glucose values in pregnancy for many decades now. It is the only blood glucose-lowering oral medication approved ...
Two medication classes reduced cardiovascular and liver events in people with type 2 diabetes
2024-06-02
BOSTON—GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Before this study, there was limited information about how these specific diabetes medications work in patients with both type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD),” said Alexander Kutz, M.D., M.P.H., M.Sc., a research fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, at Brigham ...
Neoadjuvant Immunotherapy for early stage melanoma shows positive results
2024-06-02
Immunotherapy before surgery for patients with metastatic melanoma appears to be especially successful. Fifty-nine percent of patients responds so well to this therapy that adjuvant treatment is no longer needed, according to the results of the NADINA study that were published today.
The NADINA study, led by researchers from the Netherlands Cancer Institute, was named one of the eleven clinical studies with the biggest impact on health care in 2024 by Nature Medicine. The study now proves that this was not an empty claim, as shown by the results presented by medical oncologist and research leader Christian Blank today during ASCO 2024, the international congress ...
CDC reports its decade-long efforts in standardizing vitamin D tests
2024-06-02
BOSTON—Vitamin D tests certified by the U.S. Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs (CSP) are well calibrated overall, according to a new study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. However, the researchers found some inaccuracies among the assays studied.
The blood tests show an “appropriate” level of analytical accuracy, said the study’s lead researcher, Otoe Sugahara, manager of the CDC Vitamin D Standardization-Certification Program (VDSCP) in Atlanta, Ga.
Analytical accuracy is the test’s ability to correctly analyze vitamin D in this ...
Persons of nonbinary gender may desire lower-dose testosterone treatment than guidelines recommend
2024-06-02
BOSTON—Among transgender and gender-diverse adults whose gender identity is nonbinary—not exclusively male or female—and who choose low-dose hormone treatment, most prefer to continue testosterone therapy at lower-than-recommended doses after at least six months of treatment, a new study finds. The study will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Current guidelines for initiation of testosterone for gender affirmation assume that transgender and gender-diverse, or trans, individuals desire both rapid and complete masculinization,” ...
High insulin levels contribute to worse outcomes for Black women with aggressive form of breast cancer
2024-06-02
BOSTON—High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Triple-negative breast cancer accounts for about 10-15% of all breast cancers. The term triple-negative breast cancer refers to the fact that the cancer cells do not have estrogen or progesterone receptors and do not make any or too much of the protein called HER2. The cells test ‘negative’ on all 3 tests. Triple-negative breast ...
Stress from living in violent neighborhoods tied to aggressive lung cancer in Black men
2024-06-02
BOSTON—Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“This research uncovers a previously unknown link between exposure to neighborhood violence, GR and lung tumor aggressiveness that can help us understand and fix the lung cancer health disparity seen in Black men” said Hannah Heath, B.S., a graduate research assistant ...
Thyroid eye disease patients report maintained improvement 2 years after teprotumumab infusions
2024-06-02
BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass., and published in the journal Thyroid.
“Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated. This is the case for many autoimmune diseases,” said George Kahaly, M.D., Ph.D., professor of medicine and endocrinology at Johannes Gutenberg University Medical Center in Mainz, Germany. “Given the enduring nature ...
More women report hip fractures earlier in life
2024-06-02
BOSTON—Older women with low bone density are more likely to experience their first hip fracture in their 60s compared to older ages, according to research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Older women experience an increased risk of fragility hip fractures. These are hip fractures with minimal trauma or due to a fall from a standing height, and they are often deadly and disabling,” said Avica Atri, M.D., an Internal Medicine resident physician at Jefferson Einstein Hospital in Philadelphia, Pa. “As the population over 60 swells in the United States, a large proportion of women will be ...